"Hospital que mais cresce no Maranhão, acreditado internacionalmente com o Qmentum nível Diamante."

During the past decade, Hospital Sao Domingos conducted 10 clinical trials. In the 10-year time frame, 10 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 5 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Hospital Sao Domingos" are "COVID-19" (2 trials), "Critical Illness" (2 trials), "Critically Ill Patients" (2 trials), "Acute Ischemic Stroke" (1 trials) and "Covid-19" (1 trials). Many other conditions were trialed in "Hospital Sao Domingos" in a lesser frequency.

Most popular intervention types in "Hospital Sao Domingos" are "Other" (6 trials), "Drug" (4 trials), "Device" (2 trials), "Diagnostic Test" (2 trials) and "Combination Product" (1 trials). Other intervention types were less common.

The name of intervention was led by "6MWT" (1 trials), "Antimicrobial stewardship" (1 trials), "Carbohydrate restrictive strategy" (1 trials), "Cycle ergometry exercise" (1 trials) and "Delta SOFA" (1 trials). Other intervention names were less common.

The vast majority of trials in "Hospital Sao Domingos" are 15 trials for "All" genders.

Currently, there are NaN active trials in "Hospital Sao Domingos". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 9 completed trials in Hospital Sao Domingos, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Hospital Sao Domingos, 0 "Phase 1" clinical trials were conducted, 2 "Phase 2" clinical trials and 0 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 3 trials, and there were also 2 trials that are defined as “Not Applicable".